New perspectives on the treatment of hidradenitis suppurativa

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the presence of painful nodules, abscesses, chronically draining fistulas, and scarring in apocrine gland-bearing areas of the body. The exact pathogenesis of HS is not yet well understood, but there is a consensus...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Victoria Amat-Samaranch, Eugènia Agut-Busquet, Eva Vilarrasa, Lluís Puig
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/84455840c84c462a82124ab17015a677
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:84455840c84c462a82124ab17015a677
record_format	dspace
spelling	oai:doaj.org-article:84455840c84c462a82124ab17015a6772021-11-23T23:03:44ZNew perspectives on the treatment of hidradenitis suppurativa2040-623110.1177/20406223211055920https://doaj.org/article/84455840c84c462a82124ab17015a6772021-11-01T00:00:00Zhttps://doi.org/10.1177/20406223211055920https://doaj.org/toc/2040-6231Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the presence of painful nodules, abscesses, chronically draining fistulas, and scarring in apocrine gland-bearing areas of the body. The exact pathogenesis of HS is not yet well understood, but there is a consensus in considering HS a multifactorial disease with a genetic predisposition, an inflammatory dysregulation, and an influence of environmental modifying factors. Therapeutic approach of HS is challenging due to the wide clinical manifestations of the disease and the complex pathogenesis. This review describes evidence for effectiveness of current and emerging HS therapies. Topical therapy, systemic treatments, biological agents, surgery, and light therapy have been used for HS with variable results. Adalimumab is the only US Food and Drug Administration (FDA) approved biologic agent for moderate-to-severe HS, but new therapeutic options are being studied, targeting different specific cytokines involved in HS pathogenesis. Comparing treatment outcomes between therapies is difficult due to the lack of randomized controlled trials. Treatment strategy should be selected in concordance to disease severity and requires combination of treatments in most cases.Victoria Amat-SamaranchEugènia Agut-BusquetEva VilarrasaLluís PuigSAGE PublishingarticleTherapeutics. PharmacologyRM1-950ENTherapeutic Advances in Chronic Disease, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Victoria Amat-Samaranch Eugènia Agut-Busquet Eva Vilarrasa Lluís Puig New perspectives on the treatment of hidradenitis suppurativa
description	Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the presence of painful nodules, abscesses, chronically draining fistulas, and scarring in apocrine gland-bearing areas of the body. The exact pathogenesis of HS is not yet well understood, but there is a consensus in considering HS a multifactorial disease with a genetic predisposition, an inflammatory dysregulation, and an influence of environmental modifying factors. Therapeutic approach of HS is challenging due to the wide clinical manifestations of the disease and the complex pathogenesis. This review describes evidence for effectiveness of current and emerging HS therapies. Topical therapy, systemic treatments, biological agents, surgery, and light therapy have been used for HS with variable results. Adalimumab is the only US Food and Drug Administration (FDA) approved biologic agent for moderate-to-severe HS, but new therapeutic options are being studied, targeting different specific cytokines involved in HS pathogenesis. Comparing treatment outcomes between therapies is difficult due to the lack of randomized controlled trials. Treatment strategy should be selected in concordance to disease severity and requires combination of treatments in most cases.
format	article
author	Victoria Amat-Samaranch Eugènia Agut-Busquet Eva Vilarrasa Lluís Puig
author_facet	Victoria Amat-Samaranch Eugènia Agut-Busquet Eva Vilarrasa Lluís Puig
author_sort	Victoria Amat-Samaranch
title	New perspectives on the treatment of hidradenitis suppurativa
title_short	New perspectives on the treatment of hidradenitis suppurativa
title_full	New perspectives on the treatment of hidradenitis suppurativa
title_fullStr	New perspectives on the treatment of hidradenitis suppurativa
title_full_unstemmed	New perspectives on the treatment of hidradenitis suppurativa
title_sort	new perspectives on the treatment of hidradenitis suppurativa
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/84455840c84c462a82124ab17015a677
work_keys_str_mv	AT victoriaamatsamaranch newperspectivesonthetreatmentofhidradenitissuppurativa AT eugeniaagutbusquet newperspectivesonthetreatmentofhidradenitissuppurativa AT evavilarrasa newperspectivesonthetreatmentofhidradenitissuppurativa AT lluispuig newperspectivesonthetreatmentofhidradenitissuppurativa
_version_	1718416104865398784

New perspectives on the treatment of hidradenitis suppurativa

Ejemplares similares